Cargando…
Evaluating the efficacy and microenvironment changes of HER2 + gastric cancer during HLX02 and Endostar treatment using quantitative MRI
BACKGROUND AND OBJECTIVES: Trastuzumab is an important targeted drug for HER2-positive gastric cancer. The treatment efficacy of a more cost-effective and accessible trastuzumab biosimilar, HLX02, was not well investigated, especially when combined with antiangiogenic treatment. In addition, the tum...
Autores principales: | Liang, Jianye, Dai, Wei, Li, Zhipeng, Liang, Xiangjing, Xiao, Mingjia, Xie, Chuanmiao, Li, Xinming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528101/ https://www.ncbi.nlm.nih.gov/pubmed/36192709 http://dx.doi.org/10.1186/s12885-022-10136-y |
Ejemplares similares
-
The Diagnostic Performance of Diffusion Kurtosis Imaging in the Characterization of Breast Tumors: A Meta-Analysis
por: Li, Zhipeng, et al.
Publicado: (2020) -
Monitoring the Process of Endostar-Induced Tumor Vascular Normalization by Non-contrast Intravoxel Incoherent Motion Diffusion-Weighted MRI
por: Pan, Jing-hua, et al.
Publicado: (2018) -
Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial
por: Xu, Binghe, et al.
Publicado: (2021) -
HLX in AML: novel prognostic and therapeutic target
por: Pandolfi, Ashley, et al.
Publicado: (2012) -
A DNA-Methylation-Driven Genes Based Prognostic Signature Reveals Immune Microenvironment in Pancreatic Cancer
por: Xiao, Mingjia, et al.
Publicado: (2022)